Xintela (XINT) Q3 2025 earnings summary

Executive summary

• XSTEM demonstrated strong, sustained disease-modifying effects in knee osteoarthritis, with 24-month data showing safety, pain reduction, improved joint function, and enhanced cartilage and bone structure.

• The last patient was dosed in the Phase I/IIa study for difficult-to-heal venous leg ulcers, with ongoing evaluation of safety and efficacy.

• Targinta, the oncology subsidiary, initiated a collaboration with Memorial Sloan Kettering Cancer Center for clinical development of integrin a10β1-targeted antibodies for aggressive sarcoma.

Financial highlights

• Q3 2025 income was TSEK 855, down from TSEK 2,822 year-over-year; nine-month income was TSEK 1,867, down from TSEK 3,125.

• Q3 2025 loss before tax was TSEK 10,035 (vs. TSEK 8,049); nine-month loss before tax was TSEK 32,816 (vs. TSEK 29,821).

• Loss per share for Q3 and nine months remained at SEK 0.01 and SEK 0.05, respectively.

• Cash and cash equivalents at September 30, 2025, were TSEK 3,381, with total assets of TSEK 8,641.

• Cash flow for Q3 was negative TSEK 6,756; no investments were made during the quarter.

Outlook and guidance

• Focus is on securing strategic partnerships and commercial agreements for XSTEM following positive clinical results.

• Financing efforts are ongoing, including potential capital raising and partnerships to support future development.